Closed loop with pramlintide

PreclinicalPeptide

UUniversity of Virginia

Closed loop with pramlintide is one of 24 small molecule programs targeting AML. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AMLTerminated

AMLPreclinical

Terminated

Competition

Competitive Landscape

28 competitors in AML

#DrugCompanyPhaseTrials

Fludara

Sanofi

Approved

5 2

Cytosar

Teva

Phase 3

13 3

Venclexta

AbbVie

Phase 3

8 4

Idamycin

Pfizer

Phase 3

3 5

Cerubidine

HHikma Pharmaceuticals LLC

Phase 3

4 6

Cytoxan

BBaxter Healthcare Corporation

Phase 3

3 7

Homoharringtonine

Ascentage Pharma Group Inc.

Phase 3

3 8

Vidaza

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 2

5 9

Tibsovo

SServier

Phase 2

2 10

Xospata

Astellas

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

AML1 trial

Pramlintide Combined With Model Predictive Control Algorithm

Terminated·UUniversity of Virginia·N/A·NCT01434862·2 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Closed loop with pramlintide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Closed loop with pramlintide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Closed loop with pramlintide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Virginia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Virginia

Closed loop with pramlintide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

AML1 trial

References

Drug Info

Quick Facts

Related News